Cargando…

Survival outcomes and risk group validation from SWOG S0925, a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer

BACKGROUND: Cixutumumab, a monoclonal antibody targeting insulin-like growth factor I receptor, did not improve undetectable PSA rate at 28 weeks when combined with androgen deprivation in the randomized phase II SWOG S0925 trial for patients with new metastatic hormone-sensitive prostate cancer. We...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wong, Risa L., Duong, Mai T., Tangen, Catherine M., Agarwal, Neeraj, Cheng, Heather H., Vogelzang, Nicholas J., Hussain, Maha, Thompson, Ian M., Quinn, David I., Yu, Evan Y.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423720/ https://www.ncbi.nlm.nih.gov/pubmed/32055002 http://dx.doi.org/10.1038/s41391-020-0210-x

Ejemplares similares

Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer: A Secondary Analysis of the SWOG 1216 Phase 3 Trial
por: Sayegh, Nicolas, et al.
Publicado: (2023)

Parallel (Randomized) Phase II Evaluation of Tivantinib (ARQ197) and Tivantinib in Combination with Erlotinib in Papillary Renal Cell Carcinoma: SWOG S1107
por: Twardowski, Przemyslaw W., et al.
Publicado: (2017)

Patient-reported outcomes for patients with metastatic castration-resistant prostate cancer receiving docetaxel and Atrasentan versus docetaxel and placebo in a randomized phase III clinical trial (SWOG S0421)
por: Unger, Joseph M., et al.
Publicado: (2018)

Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)
por: Synold, Timothy W., et al.
Publicado: (2019)

Hydrostatic pressure effects on the static magnetism in Eu(Fe(0.925)Co(0.075))(2)As(2)
por: Jin, W. T., et al.
Publicado: (2017)

Low-Cost Cellulase-Hemicellulase Mixture Secreted by Trichoderma harzianum EM0925 with Complete Saccharification Efficacy of Lignocellulose
por: Zhang, Yu, et al.
Publicado: (2020)

Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
por: Naing, A, et al.
Publicado: (2013)

Paclitaxel With or Without Cixutumumab as Second-Line Treatment of Metastatic Esophageal or Gastroesophageal Junction Cancer: A Randomized Phase II ECOG-ACRIN Trial
por: Stockton, Shannon, et al.
Publicado: (2023)

Body Mass Index and Weight Loss in Metastatic Colorectal Cancer in CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Update of IGF-1 receptor inhibitor (ganitumab, dalotuzumab, cixutumumab, teprotumumab and figitumumab) effects on cancer therapy
por: Qu, Xiao, et al.
Publicado: (2017)

Drug-drug interactions in subjects enrolled in SWOG trials of oral chemotherapy
por: Marcath, Lauren A., et al.
Publicado: (2021)

Phase II Trial of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Metastatic Uveal Melanoma: SWOG S0512
por: Bhatia, Shailender, et al.
Publicado: (2012)

Heterogeneously Catalyzed Pechmann Condensation Employing the Tailored Zn(0.925)Ti(0.075)O NPs: Synthesis of Coumarin
por: Jadhav, Nirajkumar H., et al.
Publicado: (2019)

IGF-Binding Proteins, Adiponectin, and Survival in Metastatic Colorectal Cancer: Results From CALGB (Alliance)/SWOG 80405
por: Guercio, Brendan J, et al.
Publicado: (2020)

Cixutumumab reveals a critical role for IGF-1 in adipose and hepatic tissue remodelling during the development of diet-induced obesity
por: Imrie, Helen, et al.
Publicado: (2022)

Pre-treatment Amino Acids and Risk of Paclitaxel-induced Peripheral Neuropathy in SWOG S0221
por: Chen, Ciao-Sin, et al.
Publicado: (2023)

Predictive factors in patients with advanced and metastatic squamous cell carcinoma of the head and neck: A study based on SWOG protocol S0420
por: MEHTA, SMITA, et al.
Publicado: (2013)

Thymidine kinase activity levels in serum can identify HR+ metastatic breast cancer patients with a low risk of early progression (SWOG S0226)
por: Bergqvist, Mattias, et al.
Publicado: (2023)

Higher capecitabine AUC in elderly patients with advanced colorectal cancer (SWOGS0030)
por: Louie, S G, et al.
Publicado: (2013)

Development and preclinical evaluation of cixutumumab drug conjugates in a model of insulin growth factor receptor I (IGF-1R) positive cancer
por: Solomon, Viswas Raja, et al.
Publicado: (2020)

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial
por: Speers, Corey W., et al.
Publicado: (2023)

Correction to: Doxorubicin plus the IGF-1R antibody cixutumumab in soft tissue sarcoma: a phase I study using the TITE-CRM model
por: Chugh, R., et al.
Publicado: (2019)

Characteristics and prognostic impact of IDH mutations in AML: a COG, SWOG, and ECOG analysis
por: Zarnegar-Lumley, Sara, et al.
Publicado: (2023)

Preparation of Eu(0.075)Tb(0.925)-Metal Organic Framework as a Fluorescent Probe and Application in the Detection of Fe(3+) and Cr(2)O(7)(2−)
por: Yin, Jie, et al.
Publicado: (2021)

An evaluation of stakeholder engagement in comparative effectiveness research: lessons learned from SWOG S1415CD
por: Bell-Brown, Ari, et al.
Publicado: (2022)

Randomized trial of medroxyprogesterone acetate for the prevention of endometrial pathology from adjuvant tamoxifen for breast cancer: SWOG S9630
por: Potkul, Ronald K, et al.
Publicado: (2016)

S0941: a phase 2 SWOG study of sorafenib and erlotinib in patients with advanced gallbladder carcinoma or cholangiocarcinoma
por: El-Khoueiry, A B, et al.
Publicado: (2014)

Immune profiling of pre- and post-treatment breast cancer tissues from the SWOG S0800 neoadjuvant trial
por: Li, Xiaotong, et al.
Publicado: (2019)

Antiviral therapy use and related outcomes in patients with cancer and viral infections: results from SWOG S1204
por: Hwang, Jessica P., et al.
Publicado: (2022)

AML risk stratification models utilizing ELN-2017 guidelines and additional prognostic factors: a SWOG report
por: Pogosova-Agadjanyan, Era L., et al.
Publicado: (2020)

Effective stakeholder engagement: design and implementation of a clinical trial (SWOG S1415CD) to improve cancer care
por: Barger, Sarah, et al.
Publicado: (2019)

A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer: SWOG S0102
por: Gralow, Julie R., et al.
Publicado: (2013)

A phase I trial of vertical inhibition of IGF signalling using cixutumumab, an anti-IGF-1R antibody, and selumetinib, an MEK 1/2 inhibitor, in advanced solid tumours
por: Wilky, B A, et al.
Publicado: (2015)

SWOG S1820: Altering Intake, Managing Symptoms for bowel dysfunction in survivors of Rectal Cancer (The AIMS-RC intervention trial)
por: Sun, Virginia, et al.
Publicado: (2021)

Image analysis-based tumor infiltrating lymphocytes measurement predicts breast cancer pathologic complete response in SWOG S0800 neoadjuvant chemotherapy trial
por: Fanucci, Kristina A., et al.
Publicado: (2023)

Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer
por: Freeman, Meredith N, et al.
Publicado: (2022)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

A phase II trial of BAY 43-9006 (sorafenib) (NSC-724772) in patients with relapsing and resistant multiple myeloma: SWOG S0434
por: Srkalovic, Gordan, et al.
Publicado: (2014)

Resistance Prediction in AML: Analysis of 4,601 Patients from MRC/NCRI, HOVON/SAKK, SWOG, and MD Anderson Cancer Center
por: Walter, Roland B., et al.
Publicado: (2014)

Enrollment of adolescents and young adults onto SWOG cancer research network clinical trials: A comparative analysis by treatment site and era
por: Roth, Michael E., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3gtjasve3a03l3e9i9elaoe4d8